enGene Corp (ENGN) - Long-Term Debt to Capital Coefficient
Localizing development in North America provides enGene Holdings Inc. (ENGN) with intellectual property protection and reliable access to capital. However, the company remains vulnerable to supply chain disruptions of specific components and external trade restrictions. This daily price action on GURU.Markets illustrates the trend for the asset, which has a debt-to-equity ratio of 0.14, while the business relies on joint clinical trials for bladder tumor treatments.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvypeoku.ae-7b8ozy8&start=20220704&end=20261101&filename=GURU_Markets_-_ENGN_-_enGene-Holdings-Inc._-_Long-Term-Debt-to-Capital "ENGN: enGene Long-Term Debt to Capital 02/21/2024 - 11/01/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for enGene Holdings Inc. (ENGN)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
- net income and valuation ratios data:
General company analysis:enGene Holdings Inc - ENGN
For enGene Holdings Inc. (ENGN), which lacks stable cash flows from finished products, the share of long-term loans within the capital structure serves as an indicator of reliance on external borrowings to sustain R&D. This metric compares liabilities with maturities exceeding one year against market capitalization, allowing investors to assess the company's financial stability and the risk of over-leverage during the early trial stages.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital protagonist-inc.com PTGX|IMVT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient KNSA (Kiniksa Pharmaceuticals, Ltd.)|Grifols Group (GRFS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Adaptive Biotechnologies Inc.|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com|Long-Term Debt to Equity Ratio BCRX (BioCryst Pharmaceuticals)|VERA (Vera Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital DNTH (Dianthus Pharma)|Ratio of Long-Term Indebtedness to Capital Pharvaris Pharma (PHVS)|ABCL - Long-Term Debt to Equity|tourmalinebio.com (TRML) - Long-Term Debt to Equity Ratio|Precigen (PGEN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|Long-Term Debt to Equity Ratio NKTR|Long-Term Debt to Capital Upstream Pharma|Long-Term Debt to Equity Zenas Biopharma Inc (ZBIO)|immunome.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital GOSS (Gossamer Bio)|KalVista Pharma (KALV) - Long-Term Liabilities to Capital|Septerna Corp - Long-Term Debt to Capital|Long-Term Liabilities to Capital Pieris Corp|Savara Inc. (SVRA) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio RIGL|ANAB (AnaptysBio) - Long-Term Debt to Capital|ATXS - Long-Term Indebtedness to Equity|Long-Term Debt to Capital RAPT|JBIO - Long-Term Liabilities to Capital|Long-Term Debt to Equity Aclaris Therapeutics ACRS|KYTX: Long-Term Debt to Capital Ratio|Tiziana Life Sciences Ltd - Long-Term Debt to Capital|Long-Term Liabilities to Capital Cabaletta Bio Inc.|VTYX (Ventyx Bio) - Long-Term Debt to Equity Ratio|Theratechnologies, Inc - Long-Term Debt to Capital Coefficient|AVTX (Avalo Therapeutics, Inc) - Long-Term Debt to Capital|ELDN: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Agenus Inc. (AGEN)|CLYM - Long-Term Liabilities to Capital|Long-Term Debt to Equity Zura Bio Limited ZURA|aTyr Pharmaceuticals - Long-Term Debt to Equity|Adagene Corp - Long-Term Debt to Capital|IMA (ImageneBio Inc) - Long-Term Debt to Capital Ratio|STTK: Long-Term Debt to Capital|EQ - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Connect Biopharma Holdings|Long-Term Debt to Capital Ratio IMUX (Immunic Inc)|Long-Term Debt to Capital ATRA|inflarx.de (IFRX) - Long-Term Indebtedness to Equity|Long-Term Debt to Equity X4 Pharmaceuticals, Inc. XFOR|Ratio of Long-Term Indebtedness to Capital Adicet Bio Inc. (ACET)|CELU: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient INMB (INmune Bio Corporation)|BRNS: Long-Term Debt to Capital|KZR - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity SAB Biotherapeutics, Inc.|Long-Term Debt to Capital Ratio AKTX (Akari Therapeutics PLC)|Long-Term Debt to Capital ENLV|Long-Term Debt to Equity Ratio q32bio.com QTTB|GeoVax Labs, Inc. - Long-Term Debt to Equity Ratio|Ratio of Long-Term Indebtedness to Capital edesabiotech.com (EDSA)|iBio - Long-Term Debt to Capital|Long-Term Liabilities to Capital Carisma Therapeutics|XTL Biopharmaceuticals, Ltd. (XTLB) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio BOLT|HCWB (HCW Biologics, Inc.) - Long-Term Debt to Capital|APVO - Long-Term Indebtedness to Equity|Long-Term Debt to Equity AIM ImmunoTech (AIM)|aditxt.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Equity GRI Bio Corp GRI|XRTX (XORTX Corp) - Long-Term Liabilities to Equity|Vyome Holdings Inc - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient REVB (revbiosciences.com)|INDP: Long-Term Debt to Capital|Scinai Immunotherapeutics Ltd (SCNI) - Long-Term Debt to Capital|Long-Term Debt to Equity CalciMedica Inc|AFMD: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Allakos Inc. (ALLK)|Long-Term Debt to Equity Ratio hookipapharma.com HOOK|Long-Term Debt to Capital IGMS (IGM Biosciences)|Long-Term Debt to Capital iTeos Therapeutics Inc ITOS|OCEA: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient TCBP (TC BioPharm Ltd)|THRD: Long-Term Debt to Capital